

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF
THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (Date of earliest event reported): September 19, 2002

COMMISSION FILE NUMBER 333-92383

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
(Exact Name of Registrant as specified in its Charter)

DELAWARE 06-1397316
(State of Incorporation) (I.R.S. Employer Identification No.)

251 BALLARDVALE STREET, WILMINGTON, MASSACHUSETTS 01887
(Address of Principal Executive Offices) (Zip Code)

978-658-6000
(Registrant's Telephone Number, Including Area Code)

ITEM 9. REGULATION FD DISCLOSURE

On September 19, 2002, Charles River Laboratories, Inc., wholly-owned subsidiary of the Registrant, posted to its company website an investor presentation, a copy of which is filed herewith as Exhibit 99.1.

EXHIBIT 99.1

Investor Presentation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, we have duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Dated: September 24, 2002

By: /s/ Dennis R. Shaughnessy

Dennis R. Shaughnessy, Sr. Vice President,
Corporate Development, General Counsel
and Secretary

[LOGO]

CHARLES RIVER LABORATORIES

Life. Science.

This document contains "forward looking statements." Such statements involve a number of risks and uncertainties that could cause actual results to differ materially from those stated or implied by the forward looking statement, including acquisition integration risks, special interest groups, contaminations, industry trends, new displacement technologies, outsourcing trends, USDA and FDA regulation, changes in law, special interest groups, continued availability of products and supplies, personnel and control, and others that are described in the Risk Factors contained in the Company's registration Statement on Form S-3, as filed on July 19, 2001. The Company disclaims any intent or obligation to update forward looking statements, and otherwise claims the safe harbor protections for forward looking statements afforded under The Private Securities Litigation Reform Act of 1995.

2

COMPANY OVERVIEW

3

CHARLES RIVER LABORATORIES

Leading provider of products and services that facilitate the discovery and development of new drugs.

4

CRITICAL PATH TO DRUG DEVELOPMENT

Discovery
Development
Clinical Trials
Regulatory Submission & Review

[GRAPH]

>5,000 New Drug Candidates
1 New Drug

Charles River's Primary Focus

5

CUSTOMER COMPOSITION

2001 Sales: \$466 million

[GRAPH]

Pharmaceutical and Biotech Companies 79%
Academic 16%
Government 5%

No Commercial Customer Accounts for More than 3% of Revenues

6

GEOGRAPHIC COMPOSITION

2001 Sales: \$466 million

[GRAPH]

North America 73%
Europe 16%

Japan 11%

7

The only global provider:
76 production and laboratory facilities in 15 countries

8

UNMATCHED INDUSTRY EXPERTISE

- o 5000 employees worldwide
 - o 20% have been with company 10 years or more
- o More than 250 scientists
- o Management team average experience -20 years

9

35 YEARS OF GROWTH & PROFITABILITY

2001 Revenues \$466 Million

[GRAPH]

2000 IPO (NYSE)

1947 Private Company

1968 Public Company (NASDAQ)

1984 Wholly-Owned Subsidiary of Bausch & Lomb

1999 Private Company/Management-Led Leverage Buyout

10

EXCEEDED WALL STREET EARNINGS
ESTIMATES IN ALL 8 QUARTERS POST-IPO

[GRAPH]

/ / First Call Consensus / / Actual

Excludes \$0.02 Q4:01 consolidation charge.

11

GROWTH IN PHARMA R&D SPENDING

- o New drug discovery targets
 - o Genomics and proteomics
- o Patent expiration

U.S. Pharmaceutical R&D Spending
(\$ in billions)

[GRAPH]

Source: 2001 PhRMA Annual Survey--U.S. Pharma R&D spending, domestic and abroad.

12

PRE-CLINICAL OUTSOURCING

Pre-Clinical R&D Spending
(\$ in billions)

[GRAPH]

13

CHARLES RIVER LABORATORIES BUSINESS SEGMENTS

14

ANIMAL RESEARCH MODELS: 40% OF REVENUES

- o More than 130 genetically and virally defined research models
- o Movement towards disease models--Diabetes, Alzheimer's, Cardiovascular
- o Mandated by FDA and global regulatory agencies

15

UNIQUE COMPETITIVE ADVANTAGES

- o Global Relationships
- o Scientific depth
- o Biosecurity

16

MARKET SHARE LEADER

2001 Worldwide Market Opportunity: \$475+ million

[GRAPH]

Charles River is 4x Larger than its Next Competitor

Source: Company estimates.

17

STRATEGIC PARTNERSHIP WITH THE JACKSON LABORATORIES

- o Premier mammalian genetic research institution
- o Hundreds of unique mouse models
- o Exclusive distribution in Europe and Japan

18

BIOMEDICAL PRODUCTS AND SERVICES

19

BIOMEDICAL PRODUCTS AND SERVICES: 60% OF CURRENT REVENUES

- o Directed at high-growth areas of drug discovery and development
 - o Discovery Services
 - o Development Services
 - o in vitro Technologies
 - o Vaccine Support Services
- o Enables customers to outsource required drug development procedures

20

LEADING MARKET SHARES

(\$ IN MILLIONS) ESTIMATED
 MARKET SIZE RANK - -----

 ----- DISCOVERY
 SERVICES Transgenic
 Services \$75-\$100 #1
 Contract Site Management
 150-200 #1 Infectious
 Disease and Genetic
 Testing 35-50 #1
 DEVELOPMENT SERVICES Drug
 Safety Assessment
 \$500-\$750 #1
 Pharmacokinetics/Metabolism
 150-175 #1(1)
 BioanalyticalChemistry
 150-175 #1(1)
 Surgery/Pharmacology 100-
 150 #1 BiosafetyTesting
 100-150 #2 Bioproduction
 Services 100-125 #2(2)
 Pathology Services 75-100
 #1 INVITRODETECTION
 SYSTEMS \$125-\$150 #1
 VACCINE SUPPORT PRODUCTS
 \$75-\$100 #1 - -----

 ----- TOTAL
 \$1,880-\$2,560 - -----

(1) High throughput MAP/BAC compound screening
 (2) Volumes for clinical trials
 Source: Company estimates.

21

DISCOVERY SERVICES

Transgenic Services

- o Facilities in US, France, Japan

Laboratory and Research Services

- o Genetic testing
- o Infectious disease testing
- o Drug efficacy testing

Contract Site Management

- o \$25 million five-year NCI-Frederick contract

4 year CAGR: 43%

22

FULL RANGE OF DEVELOPMENT SERVICES

Entire range of services to take molecule from discovery to FDA filing

- o Drug Safety Assessment
- o Pharmacokinetics / Metabolism
- o BioanalyticalChemistry
- o Surgery / Pharmacology
- o BiosafetyTesting
- o BioproductionServices
- o Pathology Services

2001 pro forma growth of 20% (4 year CAGR: 156%)

23

MAJOR ACQUISITIONS -2001

PRIMEDICA

Description Leading pre-clinical outsourcing services company
2001 Revenue \$80 million

Rationale Strengthened and complemented existing portfolio
with high value-added services

PATHOLOGY ASSOCIATES

Description World's leading provider of contract pathology
services in research models
2001 Revenue \$38 million
Rationale Expanded pre-clinical capabilities

24

MAJOR ACQUISITION - JUNE 2002

BIOLABS

Description Privately held pre-clinical outsourcing services in
Western Ireland Performs bioassay, animal health and
medical device support
2001 Revenue \$10 million
Rationale Strengthened and complemented existing portfolio with
high value-added services in the same channel
EPS Impact Accretive in 2002 by \$0.01 to \$0.02
Integration Base for expansion of our services portfolio in Europe

25

IN VITRO TECHNOLOGIES

- o Only FDA-approved alternative to animal testing
- o Endotoxintesting for injectable drug / medical device lot release

4 year CAGR: 18%

26

IN VITRO (NON-ANIMAL) TECHNOLOGIES - EXPANDED MARKET OPPORTUNITIES

[GRAPHIC]

In Vitro Pyrogen Test

Portable LAL Device

27

GROWTH STRATEGY

28

CORPORATE OBJECTIVE: DELIVER 20% ANNUAL GROWTH *

- o Same-channel
- o Outsourcing
- o Genomics and proteomics
- o Model creation
- o In vitro technologies

o Acquisitions

* Assumes 15% organic growth and 5% acquisitive growth.

29

SHIFT TO HIGHER-GROWTH
BUSINESSES

[GRAPHIC]

// RESEARCH MODELS // BIOMEDICAL PRODUCTS AND SERVICES

30

GROWTH - MORE SALES TO SAME CUSTOMERS

- Specialty PK and Toxicology by Disease Area
- Specialty Pathology
- Transgenic Model Development
- In Vitro Metabolism and Toxicology
- Drug Formulation
- Bioanalytical Chemistry
- Biopharmaceutical Production
- Pharmacokinetics & Metabolism
- Pathology Services
- In Vitro Detection Systems
- Biotech Safety Testing
- Drug Safety Assessment
- Vaccine Support Products
- Research Support Services
- Infectious Disease & Genetic Testing
- Transgenic Services
- Research Models

[GRAPHIC]

Note: Results are not to scale.

31

GROWTH THROUGH STRATEGIC ACQUISITIONS

- o 19 acquisitions and alliances since 1994
- o Same channel strategy

32

STRINGENT CRITERIA FOR ACQUISITIONS

- o Non-dilutive
- o 20% operating margin
- o 15%+ top-line growth
- o Leading player
- o Leverage worldwide infrastructure
- o Scientific leadership

33

FINANCIAL OVERVIEW

34

FINANCIAL HIGHLIGHTS

Net Sales

Research Models 4-Year CAGR:	11%
Biomedical Products & Services 4-Year CAGR:	52%

(\$ in millions)

[GRAPHIC]

// Research Models // Biomedical Products & Services

35

FINANCIAL HIGHLIGHTS (CONT'D)

Operating Income(1)
Research Models 4-Year CAGR: 29%
Biomedical Products & Services 4-Year CAGR: 58%
(\$ in millions)

[GRAPHIC]

/ / Research Models / / Biomedical Products & Services

(1) Excludes unallocated corporate overhead.

36

FINANCIAL HIGHLIGHTS (CONT'D)

EBITDA
(\$ in millions)

[GRAPHIC]

37

SOLID FINANCIAL PERFORMANCE

- o Exceeded Wall Street earnings estimates in all 8 quarters post IPO
- o Provided guidance of \$1.37 to \$1.40 for CY 2002 vs. \$0.94 for CY 2001(1)

[GRAPHIC]

/ / First Call Consensus / / Actual

(1) Excludes \$0.02 Q4:01 consolidation charge.

38

STRONG CAPITALIZATION

(\$ IN
MILLIONS) AS
OF AS OF DEC.
29, 2001 JUN.
29, 2002 ----

--- ACTUAL
ACTUAL - ----

Cash & Cash
Equivalents \$
58.3 \$ 84.7
Term Loans \$
68.6 \$ 0.0
Senior
Subordinated
Notes 78.9
0.0 Other
Debt 9.3 3.7
Senior
Convertible
Debentures
0.0 185.0 - -

 --- TOTAL
 DEBT \$ 156.8
 \$ 188.7
 Shareholder's
 Equity 286.1
 309.5 - -----

Total
 Capitalization
 \$ 442.9 \$
 498.2 Net
 Debt / Total
 Capitalization
 22.2% 20.9%
 Net Debt /
 EBITDA 0.8x
 .8x - -----

(1) Adjusted for subsequent retirements of Senior Subordinated Notes and the Senior Convertible Debenture offering.

FINANCIAL OBJECTIVES

1997 -
 2001 2002
 LONG-TERM
 CAGR
 GUIDANCE
 GROWTH
 TARGETS(2)

Revenue
 Growth 27%
 15% 20 +%
 Research
 Models 11%
 - 8% to
 10%
 Biomedical
 Products &
 Services
 52% - 30%
 to 35%
 Operating
 Income
 Growth 42%
 - 20% to
 25% Net
 Income/EPS
 Growth NA

